10x Genomics Inc
For the period ended Sep 30, 2024. Filed Oct 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 29, 2024
TXG$62.90-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net loss | $(35,753) | $(92,986) | $(133,599) | $(206,147) |
| Other comprehensive income, net of tax: | ||||
| Unrealized gains on available-for-sale marketable securities | 3 | 425 | 188 | 1,921 |
| Realized loss on available-for-sale marketable securities reclassified into net loss | 3 | — | 3 | 1,715 |
| Foreign currency translation adjustment | 456 | (133) | 270 | 22 |
| Other comprehensive income, net of tax | 462 | 292 | 461 | 3,658 |
| Comprehensive loss | $(35,291) | $(92,694) | $(133,138) | $(202,489) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.